Patents Examined by Lester L. Lee
  • Patent number: 5196404
    Abstract: This invention relates to novel biologically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding exosite association moiety (ABEAM); a linker portion of at least 18 .ANG. in length; and a thrombin catalytic site-directed moiety (CSDM). This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.
    Type: Grant
    Filed: July 6, 1990
    Date of Patent: March 23, 1993
    Assignees: Biogen, Inc., Health Research, Inc.
    Inventors: John M. Maraganore, John W. Fenton, II, Toni Kline
  • Patent number: 5194588
    Abstract: The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.
    Type: Grant
    Filed: March 9, 1990
    Date of Patent: March 16, 1993
    Assignee: ICI Americas Inc.
    Inventors: Philip D. Edwards, John A. Schwartz, Mark M. Stein, Diane A. Trainor, Richard A. Wildonger
  • Patent number: 5194581
    Abstract: The invention relates to poly(phosphoesters), compositions comprising the poly(phosphoesters), and methods of use.
    Type: Grant
    Filed: March 9, 1989
    Date of Patent: March 16, 1993
    Inventor: Kam W. Leong
  • Patent number: 5192545
    Abstract: Specific inorganic silica gels are used as an adsorbent drying agent for controlling insect pests in a structure. When it is too humid in the structure, the silica gels adsorb moisture. On the other hand, when it is too dry in the structure, the silica gels supply moisture. The silica gels thus create the environment where household insect pests cannot survive. Moreover, by exposing invading insect pests to silica-gel particles, the pests' tissues are physiologically decayed, and the population density of the insect pests is decreased. Insect pests in the structure can be thus controlled using the silica gels.
    Type: Grant
    Filed: December 9, 1991
    Date of Patent: March 9, 1993
    Assignee: Fuji-Davison Chemical Ltd.
    Inventor: Yoshito Nakashima
  • Patent number: 5192746
    Abstract: Cyclized integrin receptor antagonist compounds useful in modulating cell adhesion to integrin receptors, including adhesion related to fibronectin and/or fibronectin receptors, are disclosed. Methods for synthesizing, testing, formulating, and using the compounds as therapeutic agents are also disclosed.
    Type: Grant
    Filed: July 9, 1990
    Date of Patent: March 9, 1993
    Assignee: Tanabe Seiyaku Co., Ltd.
    Inventors: Thomas J. Lobl, Shiu-Lan Chiang, Pina M. Cardarelli
  • Patent number: 5190920
    Abstract: Compounds and compositions comprising fragments and methods for using synthetic analogs of thrombospondin for promoting or inhbiting thrombospondin-like activity are provided.
    Type: Grant
    Filed: September 24, 1990
    Date of Patent: March 2, 1993
    Assignee: W. R. Grace & Co.-Conn.
    Inventors: Jacob Eyal, Bruce K. Hamilton, George P. Tuszynski
  • Patent number: 5190918
    Abstract: Compounds and compositions comprising fragments and synthetic analogs of human thrombospondin are provided together with methods for their use as thrombospondin-like agents.
    Type: Grant
    Filed: February 22, 1990
    Date of Patent: March 2, 1993
    Assignees: W. R. Grace & Co.-Conn., The Medical College of Pennsylvania
    Inventors: Alan H. Deutch, George Tuszynski
  • Patent number: 5190921
    Abstract: These compounds are represented by formula (I), in which each of R.sub.1 R.sub.2 =H, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.7 cycloalkyl, or aromatic; (when R.sub.1 =H, R.sub.2 can be an amine function-protecting radical, amino acid residue or peptide fragment; R.sub.1 and R.sub.2 being capable of forming, with N, a 5-7 component ring); A=carbonyl or methylene; W=hydroxy, phenoxy, C.sub.1 -C.sub.8 alkoxy; phenoxy(C.sub.1 -C.sub.8 alkyl), amino, (C.sub.1 -C.sub.8 alkyl)amino, di(C.sub.1 -C.sub.8 alkyl)amino, (when A=carbonyl, W=amino acid residue or peptide fragment); Y=--OSO.sub.2 OR.sub.3 (II), --OPO(OR.sub.3).sub.2 (III), --(CH.sub.2 (.sub.m --SO.sub.2 OR.sub.3 (IV) or --(CH.sub.2).sub.m --PO(OR.sub.3).sub.2 (V) [R.sub.3 =H, C.sub.1 -C.sub.8 alkyl; m=1 to 4]; Z=cyclohexane, pyridyl or phenyl; n=0 to 4; on the condition that when Y=(II) or (III), -A-W is other than a sequence composed of natural amino acids.
    Type: Grant
    Filed: January 24, 1992
    Date of Patent: March 2, 1993
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Bernard P. Roques, Isabelle Marseigne, Bruno Charpentier
  • Patent number: 5188824
    Abstract: Stable, aqueous emulsion formulations of water-insoluble organic pesticides are formed from a mixture of (1) a water-insoluble organic pesticide, (2) a water based structured particle latex containing nonionic particles to which is bound a layer containing stabilizing pH independent ionic groups chemically bound at or near the surface of the polymer particles, and optionally a cosolvent and/or a cosurfactant for the pesticide. The resulting product is much more stable to coalescence than emulsions made with conventional surfactants.
    Type: Grant
    Filed: September 23, 1991
    Date of Patent: February 23, 1993
    Assignee: DowElanco
    Inventors: Ritchie A. Wessling, Dale M. Pickelman, Dennis G. Wujek
  • Patent number: 5188827
    Abstract: A method for lowering the blood-serum cholesterol levels in mammals by administering IL-4 is disclosed as well as the use of IL-4 for the manufacture of a medicament for use in lowering blood-serum cholesterol levels.
    Type: Grant
    Filed: June 10, 1991
    Date of Patent: February 23, 1993
    Assignee: Schering Corporation
    Inventor: Hugh E. Black
  • Patent number: 5187155
    Abstract: A number of novel anticoagulant peptides are claimed. These include V-V-I-K-H-N-R-F-T-K-E-T-Y-D-F-D-I, A-V-L-R-L-K-T-P-I-T-F-R-M-N-V-A-P-A-C-L, A-F-L-K-W-I-D-R-S-M-K-T-R-G-L, T-E-Q-E-E-G-G-E-A-V-H-E-V-E-V-V-I-K, L-L-I-N-E-E-N-E-G-F-G-G, C-L-Y-Q-A-K-R-F-K-V-R-V-G-D-R-N-T-E-Q-E-E-G-G-E-A-V, E-Q-E-E-G-G-E-A-V-H-E-V-E-V-V-I, and F-C-A-G-Y-T-D-K-Q-E-D-A-C and their analogues are claimed. The peptides are useful for inhibiting activation of Factor X and/or function of Factor Xa.
    Type: Grant
    Filed: June 23, 1989
    Date of Patent: February 16, 1993
    Assignee: Board of Regents, The University of Texas System
    Inventor: Daryl S. Fair
  • Patent number: 5185324
    Abstract: The present invention relates to compounds of the general formula I ##STR1## in which A denotes a radical from the group comprising S, SO, SO.sub.2, O, CO, CS or a direct bond,B denotes the radical of an amino acid andD denotes a CH.sub.2 group or a radical --NR.sup.7 --, where R.sup.7 can be hydrogen or a (C.sub.1 -C.sub.4)alkyl radical;and in which R.sup.1 to R.sup.4 are defined as indicated in the description, to a process for the preparation thereof, to agents containing these, and to the use thereof.
    Type: Grant
    Filed: December 12, 1989
    Date of Patent: February 9, 1993
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Wolfgang Ruger, Hansjorg Urbach, Dieter Ruppert, Bernward Scholkens
  • Patent number: 5183805
    Abstract: A biologically active cyclic synthetic peptide analog having an amino acid sequence similar to that of native epidermal growth factor between amino acids 32-48 is revealed. The peptide has been found to mimic certain biological activities of intact native epidermal growth factor (EGF). The EGF peptide analogs of the present invention include at least one sulfhydryl bond between two cysteines of the peptide containing block termini. The peptides comprise the end of the B-loop and the C-loop characteristic of the native form of the epidermal growth factor peptide. The biological activity of the peptide provides for methods of using the peptide as an agent in wound healing and also in cancer therapy. More particularly, the described peptides are used in cancer therapeutic applications and in the promotion of wound healing, especially burn wounds and peptic ulcer disease. Methods of preparing and using the described bioactive EGF analog peptides are also disclosed.
    Type: Grant
    Filed: August 13, 1990
    Date of Patent: February 2, 1993
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jin S. Lee, Mark Blick
  • Patent number: 5183657
    Abstract: The use of antibodies against human alpha tumor necrosis factor in antilymphocyte antibody therapy is described. The anti-human alpha tumor necrosis factor antibodies may be used to prevent or treat shock-related conditions arising from antilymphocyte antibody therapy. Also described are compositions containing anti-human alpha tumor necrosis factor antibodies and antilymphocyte antibodies, as well as recombinant anti-human alpha tumor necrosis factor antibodies.
    Type: Grant
    Filed: May 7, 1992
    Date of Patent: February 2, 1993
    Assignee: Celltech Limited
    Inventor: Wim Buurman
  • Patent number: 5182261
    Abstract: This invention relates to transforming growth factor alpha modified by replacement of an L-amino acid residue with a D-amino acid residue and pharmaceutical compositions thereof useful in wound healing, ulcer treatment or trauma.
    Type: Grant
    Filed: July 13, 1989
    Date of Patent: January 26, 1993
    Assignee: The Rockefeller University
    Inventor: James P. Tam
  • Patent number: 5182366
    Abstract: A method of preparing a mixture of peptides having a known composition and containing a peptide of a desired amino acid sequence is disclosed. The method involves three essential steps. First a given amount of a mixture of amino acyl or peptide derivatized resin is divided into a number of pools with each pool containing an equal molar amount of the resin mixture. Second a different single amino acid is coupled to the resin mixture in each of the pools and the coupling reaction is driven to completion. The peptide mixtures in each of the pools are then mixed together to obtain a complex peptide mixture containing each peptide in retrievable and analyzable amounts. The steps can be repeated to lengthen the peptide chains and methods can be employed to retrieve the desired peptide from the mixture and carry out analyses such as the determination of the amino acid sequence.
    Type: Grant
    Filed: May 15, 1990
    Date of Patent: January 26, 1993
    Inventors: Verena D. Huebner, Daniel V. Santi
  • Patent number: 5180711
    Abstract: The present invention relates to a method of controlling gonadotropin levels in mammals which comprises administering a gonadotropin releasing hormone (GnRH) antagonist in an amount and frequency effective to substantially suppress endogenous gonadotropin levels in said mammal and administering gonadotropin releasing hormone (GnRH) in an amount and frequency effective to induce secretion of gonadotropins to maintain a desired level in said mammal. This method is especially useful for treating mammals, particularly women, who suffer from polycystic ovarian disease or hyperandrogenism, or who otherwise have abnormally high levels of luteinizing hormone which it is desired to reduce to approximately normal levels. The method of this invention is particularly advantageous for inducing ovulation in mammals, particularly women, that have the above-mentioned problems. The preferred GnRH antagonists for use in the present invention include Antide and its analogs, which exhibit long term gonadotropin suppression.
    Type: Grant
    Filed: June 14, 1990
    Date of Patent: January 19, 1993
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventor: Gary D. Hodgen
  • Patent number: 5178856
    Abstract: A therapeutic method for treating mammals by administering an effective dosage of a substance comprising interleukin 6 and interleukin 3 into the mammal for enhancing the growth of megakaryocytes and platelets.
    Type: Grant
    Filed: May 15, 1991
    Date of Patent: January 12, 1993
    Assignee: Board of Regents of the University of Oklahoma
    Inventor: Samuel A. Burstein
  • Patent number: 5177059
    Abstract: Polymyxin B carrier conjugates, especially polymyxin B-dextran, are water soluble, have a greater half-life in the bloodstream and are significantly less toxic than native polymyxin B.
    Type: Grant
    Filed: November 1, 1990
    Date of Patent: January 5, 1993
    Assignee: Sandoz Ltd.
    Inventors: Dean A. Handley, Philip Lake
  • Patent number: 5177061
    Abstract: Methods and compositions for (a) stimulating the growth of hair in warm-blooded animals, (b) increasing subcutaneous fat in warm-blooded animals, and (c) increasing the density of hair follicles in warm-blooded animals are disclosed. The methods utilize an effective amount of a composition comprising a derivative of GHL-Cu.
    Type: Grant
    Filed: September 22, 1989
    Date of Patent: January 5, 1993
    Assignee: ProCyte Corporation
    Inventor: Loren R. Pickart